Genoplex Selected as Showcase Presenter at American Urological Association Innovation Nexus

Boulder, CO – January 14, 2026 – Genoplex, a leading health technology company dedicated to connecting healthcare providers and patients to life-saving advanced therapies at qualified treatment centers, today announced it has been selected as aShowcase Presenter at the American Urological Association (AUA) InnovationNexus, to be held in May 2026. Click here to see the full list of Showcase Presenters.

Launched in 2023, the AUA Innovation Nexus was created to ignite discovery and accelerate innovation by addressing a critical gap in the healthcare innovation pipeline.The program convenes urologists, researchers, startups, investors, and industry leaders to collaborate, receive mentorship, and translate promising ideas into real-world clinical impact.

Genoplex was selected for its work addressing one of the most pressing challenges in modern urologic oncology: the real-world integration of radioligand therapies (RLTs)into U.S. clinical practice. While PSMA-targeted RLTs have demonstrated significant improvements in overall survival, progression-free survival, and quality of life for men with advanced prostate cancer, adoption across the United States has been slowed by substantial operational and coordination barriers.

According to published clinical and operational analyses, successful RLT delivery requires extensive multidisciplinary coordination across urology, medical oncology, nuclear medicine, radiation safety, pharmacy, and administrative teams. Health systems face high upfront infrastructure costs, complex Nuclear Regulatory Commission (NRC)licensing requirements, limited availability of PSMA PET imaging, fragmented referral pathways, reimbursement complexity, and time-sensitive supply chain constraints for radio pharmaceuticals - all of which can delay patient access by weeks or months.

Genoplex’s Advanced Therapy Connect™ platform was purpose-built to address these challenges. Using an agentic AI architecture, the platform automates patient identification, eligibility screening, digital intake, and referral orchestration - connecting community urologists and oncologists with qualified nuclear medicine and theranostics centers. By streamlining workflows, improving multidisciplinary communication, and reducing administrative friction, Genoplex aims to shorten time from diagnosis to treatment and help health systems scale RLT programs safely and efficiently.

“Radioligand therapy represents a major breakthrough for patients with advanced prostate cancer, but innovation in treatment must be matched by innovation in care delivery,” said Christopher Leidli, CEO of Genoplex. “We built Genoplex to solve the operational and referral bottlenecks that prevent eligible patients from reaching RLT centers in time. Being selected by the AUA Innovation Nexus validates the importance of this work and the role digital infrastructure plays in the future of urologic care.”

As a Showcase Presenter, Genoplex will demonstrate how AI-enabled care orchestration can support RLT readiness by improving referral accuracy, coordinating multidisciplinary workflows, facilitating digital intake and prior authorization processes, and enabling scalable expansion of theranostics service lines - without requiring major IT overhauls.

The AUA Innovation Nexus positions itself not just as an incubator, but as a movement-one that brings together medicine, business, and technology to advance ideas from concept to clinical impact. Genoplex’s selection reflects the growing recognition that solving access challenges for advanced therapies like RLT is essential to fully realizing their life-extending and quality-of-life benefits for patients.

About Genoplex

Genoplex is a health technology company transforming how patients are identified, referred, and connected to advanced therapies, including cell therapies, gene therapies, and radiopharmaceuticals. Its flagship platform, Advanced Therapy Connect™, uses agentic AI and interoperable digital infrastructure to modernize patient intake, referral, and care coordination -reducing time from diagnosis to treatment and expanding access to personalized medicine. For more information, visit www.genoplex.ai.

Media Contact

Genoplex, Inc.
info@genoplex.ai
www.genoplex.ai

Genoplex Recognized as Quarterfinalist for the 2025 Digital Health Hub Foundation: Digital Health Awards

Boulder, CO – September 23, 2025 – Genoplex, a leading health technology company dedicated to connecting healthcare providers and patients to life-saving advanced therapies at qualified hospital treatment centers, is thrilled to announce its selection as a quarterfinalist for the prestigious 2025 Digital Health Hub Foundation: Digital Health Awards. Genoplex was chosen as a quarterfinalist for the category - AI in Healthcare Operations.

The AI in Healthcare Operations category highlights AI technologies that enhance operational efficiency, reduce administrative burden, and streamline healthcare delivery behind the scenes. It includes solutions for workflow automation, revenue cycle management, clinical documentation, resource optimization, and predictive analytics to help health systems run smarter, leaner, and more sustainably.

This recognition highlights Genoplex for its significant contributions to expanding patient access to life-saving advanced therapies. The Digital Health Hub Awards celebrate organizations that demonstrate excellence in leveraging digital advancements to enhance healthcare services and patient outcomes. Being named a quarterfinalist reflects our commitment to driving meaningful change in the healthcare landscape

Out of a substantial pool of over 1,800 submissions, only the most promising 16 quarterfinalists per category, per track have advanced to this stage.

“The 2025 Awards have once again raised the bar, drawing an unprecedented range of global submissions that highlight the rapid evolution of AI and impact of digital health. Congratulations to all of our quarterfinalists for pushing the boundaries of what’s possible and driving meaningful change in healthcare,” said Mark H. Goldstein, Chairman of the Digital Health Hub Foundation.

Finalists will be announced October 4, 2025.

About Digital Health Hub Foundation:

Our mission is to help the world’s next best innovative healthcare companies scale and grow. Founded in 2017, on the campus of UCSF in San Francisco, our now 30,000 member community consists of thousands of early-to late-stage healthcare companies and highly qualified healthcare industry providers, payors, experts, mentors, investors, clinicians and researchers who participate in our annual awards ceremony where we bring together the industry to honor and validate the best of the best and celebrate the technological advances in healthcare and the impact it has

About Genoplex:

Genoplex is a leading health technology company dedicated to democratizing patient access to advanced therapies. Powered by the Advanced Therapy Connect™ platform, Genoplex leverages AI to connect patients to life-saving treatments and streamline healthcare provider workflows. Headquartered in Boulder, CO, Genoplex partners with leading hospital treatment centers and pharmaceutical manufacturers to transform the advanced therapy patient access landscape. For more information, visit www.genoplex.ai

Genoplex Announces Partnership with NVIDIA to Redefine Care with AI that Connects Patients to Advanced Therapies

Boulder, CO – December 11, 2024 – Genoplex, a leading health technology company dedicated to connecting healthcare providers and patients to life-saving advanced therapies through its AI-powered Advanced Therapy Connect™ platform,today announced that it is joing the NVIDIA Inception program for start-ups. This collaboration will leverage NVIDIA’s AI infrastructure and expertise to enhance thecapabilities of Genoplex’s digital agent, accelerating patient referrals and reducingtime from diagnosis to treatment.

Genoplex’s Advanced Therapy Connect platform streamlines patient access to therapies such as cell and gene therapies, and radiopharmaceuticals while also reducing complexity and administrative burden of care coordination for healthcareprofessionals at qualified treatment centers.

By integrating NVIDIA’s cutting-edge AI microservices, including the NVIDIA CUDA-X platform and the NeMo framework, Genoplex will expand its ability to process vast datasets, support scalable AI model deployment, and develop innovative domain-specific AI solutions. These enhancements will enable delivery of end-to-end real-time patient journey data, clinical workflow integration, and predictive analytics specific to advanced therapies, including cell therapies, gene therapies and radiopharmaceuticals.

Key initiatives under this partnership include:

High-Performance AI Models for Patient Referral and Workflow Optimization: NVIDIA’s microservices will enable Genoplex’s digital agent to improve patient identification and shorten the time from referral to patient intake while streamlining healthcare provider workflows with low-latency AI model deployment.

Large-Scale Multi-Modal Data Processing: Leveraging NVIDIA’s CUDA-Xplatform, Genoplex will accelerate the processing of clinical, genomic, and operational data to refine its proprietary AI algorithms. This will support precise and timely connections between patients and healthcare providers.

Development of Advanced Medical Large Language Models (LLMs): By integrating NVIDIA’s NeMo framework, Genoplex will enhance its conversational AI capabilities to support healthcare providers with real-time,actionable insights for treatment pathways, clinical decision-making, and patient engagement.

"AI is transforming how healthcare providers connect patients with advanced therapies. Through this collaboration, NVIDIA’s platform technologies will enable Genoplex to accelerate AI model development and scale its transformative solutions to democratize patient care.”  said Christopher Leidli, CEO of Genoplex.
‍
“With NVIDIA’s unparalleled AI expertise, we are poised to set a new standard for how patients access these life-saving treatments. Together, we are empowering healthcare providers with AI-driven tools to ensure no patient is left behind.”

About Genoplex:

Genoplex is a leading health technology company dedicated to democratizing patient access to advanced therapies. Powered by the Advanced Therapy Connect™ platform, Genoplex leverages AI to connect patients to life-saving treatments and streamline healthcare provider workflows. Headquartered in Boulder, CO, Genoplex partners with leading hospital treatment centers and pharmaceutical manufacturers to transform the advanced therapy patient access landscape.

New News Section on Our Website

We are excited to announce the launch of a news section on our website! This space will serve as a hub for all updates related to Genoplex and our platform, AdvancedTherapiesConnect.com. Stay tuned for the latest news, insights, and innovations in the field of advanced therapies.